Nursing Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Mediators Inflamm. 2022 Jul 23;2022:5665778. doi: 10.1155/2022/5665778. eCollection 2022.
Inflammatory bowel disease (IBD) is a chronic autoimmune disorder stemming from unrestrained immune activation and subsequent destruction of colon tissue. Genetic susceptibility, microbiota remodeling, and environmental cues are involved in IBD pathogenesis. Up to now, there are limited treatment options for IBD, so better therapies for IBD are eagerly needed. The therapeutic effects of naturally occurring compounds have been extensively investigated, among which quercetin becomes an attractive candidate owing to its unique biochemical properties. To facilitate the clinical translation of quercetin, we aimed to get a comprehensive understanding of the cellular and molecular mechanisms underlying the anti-IBD role of quercetin. We summarized that quercetin exerts the anti-IBD effect through consolidating the intestinal mucosal barrier, enhancing the diversity of colonic microbiota, restoring local immune homeostasis, and restraining the oxidative stress response. We also delineated the effect of quercetin on gut microbiome and discussed the potential side effects of quercetin administration. Besides, quercetin could serve as a prodrug, and the bioavailability of quercetin is improved through chemical modifications or the utilization of effective drug delivery systems. Altogether, these lines of evidence hint the feasibility of quercetin as a candidate compound for IBD treatment.
炎症性肠病（IBD）是一种慢性自身免疫性疾病，源于免疫激活失控，随后结肠组织遭到破坏。IBD 的发病机制涉及遗传易感性、微生物组重构和环境线索。到目前为止，IBD 的治疗选择有限，因此迫切需要更好的 IBD 治疗方法。天然存在的化合物的治疗效果已经得到了广泛的研究，其中槲皮素由于其独特的生化特性成为一个有吸引力的候选物。为了促进槲皮素的临床转化，我们旨在全面了解槲皮素在抗 IBD 中的细胞和分子机制。我们总结到，槲皮素通过巩固肠道黏膜屏障、增强结肠微生物组的多样性、恢复局部免疫平衡和抑制氧化应激反应来发挥抗 IBD 作用。我们还描述了槲皮素对肠道微生物组的影响，并讨论了槲皮素给药的潜在副作用。此外，槲皮素可以作为前药，通过化学修饰或利用有效的药物传递系统来提高槲皮素的生物利用度。总而言之，这些证据表明槲皮素作为 IBD 治疗候选化合物的可行性。
